Acute Ischemic Stroke pipeline therapeutics constitutes close to 27 molecules. Out of which approximately 27 molecules are developed by Companies. latest report Acute Ischemic Stroke – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Request for sample @ https://marketreportscenter.com/request-sample/438521
Acute Ischemic Stroke Acute ischemic stroke is caused by a blockage in a blood vessel that stops the blood flow. The surrounding brain tissue becomes deprived of oxygen. Symptoms of acute ischemic stroke include loss of sensation and weakness in an arm, leg or one side of the body, partial loss of vision or hearing, slurred speech, double vision and dizziness. The predisposing factors include age, race, high blood pressure, diabetes mellitus, tobacco smoking, obesity, obstructive sleep apnea and dyslipidemia. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 9, 5, 1 and 9 respectively.
Check Discount on report @ https://marketreportscenter.com/request-discount/438521
Furthermore, this report also reviews of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects. Driven by data built using data and information sourced from Our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more details of report, table of content, purchase copy of report visit https://marketreportscenter.com/reports/438521/acute-ischemic-stroke-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center